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Dear Sir,
We enjoyed reading the position paper by the Italian Society on Thrombosis and 
Haemostasis (SISET) that was recently published in Blood Transfusion1. It stands 
out as a rational and well-balanced document in a time of often confused and 
emotionally-charged initiatives in the management of COVID-19, a severe disease 
about which still not enough is known2. We would like to focus our attention 
on the recommendation to urgently organise randomised clinical trials (RCT), 
hopefully supported by the Italian drug agency (AIFA), comparing standard 
low-dose unfractionated or low molecular weight heparin (LMWH) with higher doses 
for thromboprophylaxis of COVID-19 patients, who are apparently at very high risk for 
venous thromboembolism (VTE)3. 
In partial disagreement with the authors, we think that RCT are necessary not only 
to validate the full anticoagulant dose, but also the intermediate-low dose LMWH 
(enoxaparin 4,000 IU subcutaneously b.i.d.). We have designed an RCT, X-COVID 19, 
which has been approved by the AIFA. It will compare eff﻿icacy (prevention of VTE) and 
safety (incidence of major/clinically relevant bleeding) of the standard prophylactic dose 
of subcutaneous enoxaparin (4,000 IU o.d.) with those of a higher dose (4,000 IU b.i.d.). 
We plan to randomise 2,712 COVID-19 patients, hospitalised on non-Intensive Care 
Unit (ICU) wards. The primary endpoint will be incidental events of asymptomatic 
or symptomatic deep vein thrombosis (DVT) diagnosed by serial compression 
ultrasonography (CUS) or symptomatic pulmonary embolism diagnosed by computed 
tomography angiography (CTA). We will also evaluate the possibility that double-dose 
enoxaparin favourably impacts the natural history of the disease, perhaps decreasing 
the incidence of the organ dysfunction associated with the formation of microthrombi 
in vital organs4. 
Regarding this last point, we would like to question the view that most of the pulmonary 
occlusions that are detected in COVID-19 patients are caused by pulmonary emboli, 
originating from peripheral venous thrombi. None of the over 300 COVID-19 patients 
hospitalised on our wards (all treated with 4,000 IU enoxaparin o.d.), including those 
with evidence of pulmonary artery occlusions, displayed signs and symptoms of DVT; 
some of them underwent CUS, which failed to detect asymptomatic DVT5. More 
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importantly, the f﻿illing defects of pulmonary vessels 
that were detected by CTA were, in most cases, more 
reminiscent of pulmonary thrombi than of emboli, 
because they were not fully occlusive. This observation is 
compatible with post-mortem descriptions of presence of 
thrombotic or thrombo-haemorrhagic microangiopathy 
in the pulmonary vessels, which likely developed locally 
as a consequence of a thrombo-inf lammatory process 
that may not necessarily be counteracted by high-dose 
enoxaparin. 
Indeed, too much remains unknown about this terrible 
disorder and more information is urgently needed. This 
can be achieved by rigorously conducted studies.
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